The investment comes after SK's yearlong search for partnership opportunities to support SK Group's pledge to contribute to achieving the global carbon emission reduction target; The partnership is set to take SK a step closer to the completion of its green energy portfolio TerraPower also has technologies to produce medical radioisotopes, which have potential synergies with SK's biotech businessNEW YORK, Aug. 15, 2022 /PRNewswire/ -- The longstanding commitment to carbon emission reduction and continued search for partnership opportunities have led to investments in a global energy pioneer, taking SK a step closer to completing its green energy portfolio. Aside from SMR, TerraPower also has technologies to produce the medical radioisotope actinium-225 (Ac-225). Ac-225 is one of the most promising radionuclide raw materials that is being incorporated into investigational products by drug developers for targeted alpha therapy (TAT), which can kill targeted cancer cells while sparing normal cells. , TerraPower is a leading nuclear innovation company with the capability to design sodium-cooled fast reactor (SFR), a type of advanced nuclear reactors. "TerraPower is committed to solving some of the toughest challenges that face this generation through innovation," said TerraPower President and CEO Chris Levesque.